Review
Oncology
Yuichi Kumaki, Goshi Oda, Sadakatsu Ikeda
Summary: MET gene is a crucial oncogene in cellular proliferation. Therapies targeting MET amplification have shown promising results. However, distinguishing between focal amplification and polysomy is a challenge, requiring comparative measures. Careful patient selection is important for optimizing therapeutic efficacy, as the effectiveness of MET inhibitors can vary depending on the extent of amplification. Future research should focus on determining the ideal threshold for MET amplification, finding the most effective combination therapies, and developing novel targeted treatments for MET amplification patients.
Article
Oncology
Seongjae Kim, Jung Min Park, Soeun Park, Eunsun Jung, Dongmi Ko, Minsu Park, Juyeon Seo, Kee Dal Nam, Yong Koo Kang, Kyoungmin Lee, Lee Farrand, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Summary: DOXA demonstrates significant anti-proliferative effects on TNBC cells by inducing apoptosis through caspase activation. Molecular docking studies reveal direct interaction of DOXA with the tyrosine kinase domains of c-MET and EGFR. DOXA disrupts important survival pathways and suppresses CSC-like characteristics, indicating its potential as a therapeutic option for metastatic TNBC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Cell Biology
Shouyang Song, Zhen Yu, Yajing You, Chenxi Liu, Xiaoyu Xie, Huanran Lv, Feng Xiao, Qiang Zhu, Chengyong Qin
Summary: This study confirms the crucial role of EGFR/MET in HCC, as they promote liver cancer metastasis by regulating signaling pathways and resisting immune attacks.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Pinar Ozden Eser, Raymond M. Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti H. Dholakia, Jihyun Choi, Yoonji Eum, Atsuko Ogino, Pavlos Missios, Dalia Ercan, Man Xu, Michael J. Poitras, Stephen Wang, Kenneth Ngo, Michael Dills, Masahiko Yanagita, Timothy Lopez, Mika Lin, Jeanelle Tsai, Nicolas Floch, Emily S. Chambers, Jennifer Heng, Rana Anjum, Alison D. Santucci, Kesi Michael, Alwin G. Schuller, Darren Cross, Paul D. Smith, Geoffrey R. Oxnard, David A. Barbie, Lynette M. Sholl, Magda Bahcall, Sangeetha Palakurthi, Prafulla C. Gokhale, Cloud P. Paweletz, George Q. Daley, Pasi A. Janne
Summary: Some EGFR-mutant, MET-amplified lung cancers may develop dependence on MET activation alone, suggesting that these patients could be treated with a single-agent MET TKI instead of the current standard-of-care EGFR and MET inhibitor combination regimens.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Dongsheng Wang, Yue Lu, Sreenivas Nannapaneni, Christopher C. Griffith, Conor Steuer, Guoqing Qian, Xu Wang, Zhengjia Chen, Mihir Patel, Mark El-Deiry, Dong M. Shin, Xia He, Zhuo G. Chen, Nabil F. Saba
Summary: Combination therapy targeting EGFR, HER2, and c-Met was found to be more effective in inhibiting SCCHN cell growth and inducing apoptosis compared to single agent therapy. The combinations also demonstrated superior efficacy in tumor growth inhibition in PDX models. These findings support further clinical investigation of such combinations in SCCHN.
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Jian-Hua Luo, Silvia Liu, Junyan Tao, Bao-Guo Ren, Katherine Luo, Zhang-Hui Chen, Michael Nalesnik, Kathleen Cieply, Tianzhou Ma, Shi-Yuan Cheng, Qi Chen, George K. Michalopoulos, Joel B. Nelson, Rohit Bhargava, Jun Zhang, Deqin Ma, David Jarrard, Arjun Pennathur, James D. Luketich, Donald B. DeFranco, Satdarshan Paul Monga, George Tseng, Yan-Ping Yu
Summary: The fusion gene Pten-NOLC1, derived from Pten gene, is a driver for human cancers as it promotes cancer proliferation, growth, invasion, and metastasis. Its presence in primary cancer samples and cancer cell lines from different organs suggests its significance in oncogenesis.
Article
Oncology
Yuying Zhu, He Zhang, Xingxing Han, Zhiyong Wang, Yanfen Cui, Ran Tian, Zhaosong Wang, Baoai Han, Jianfei Tian, Fei Zhang, Ruifang Niu
Summary: Chemotherapy remains the most common treatment for breast cancer, but chemoresistance in tumors is a major obstacle. Chemoresistant cells have evolved a novel STAT3-C-MET feed-forward loop to sustain cell proliferation. C-MET and EGFR family signaling pathways function independently to maintain the proliferation of resistant cells.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alessandra Cavaliere, Suxia Sun, Supum Lee, Jacob Bodner, Ziqi Li, Yiyun Huang, Sheri L. Moores, Bernadette Marquez-Nostra
Summary: In this study, a novel bispecific antibody, [Zr-89]ZrDFO-amivantamab, was successfully developed and evaluated for its pharmacologic and imaging properties compared to its single-arm antibodies and non-specific isotype controls. The results showed that [Zr-89]ZrDFO-amivantamab demonstrated the greatest uptake in tumors co-expressing EGFR and c-MET.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Biochemistry & Molecular Biology
Diksha A. Varma, Mrityunjay Singh, Sharad Wakode, N. E. Dinesh, Simran Vinaik, Shailendra Asthana, Manisha Tiwari
Summary: This study used structure-based pharmacophore mapping and virtual screening to identify a compound SN00020821 from a natural source that can simultaneously interact with c-MET, EGFR, and VEGFR-2 receptor tyrosine kinases. The compound showed good interaction energies with all three targets and stable key interactions with critical amino acids. It also met the requirements for drug-likeness.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Oncology
Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R. Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C. Thai, Koji Haratani, Yurie Yamamoto, Shriram K. Sundararaman, Erik H. Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P. Paweletz, Juan J. Miret, Patrick H. Lizotte, Prafulla C. Gokhale, Pasi A. Janne, David A. Barbie
Summary: This study reveals that MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment.
Article
Biophysics
Dan Xiao, Yongxiong Huang, Shuaihao Huang, Jianxiong Zhuang, P. Chen, Yi Wang, Lei Zhang
Summary: In this study, a biocompatible RNA nanoparticle delivery system was constructed for specific targeting to chordomas cells and encapsulating the drug paclitaxel. The results demonstrated that this system exhibited excellent specific targeting ability and enhanced the inhibition efficiency of chordomas tumor cells.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Biochemistry & Molecular Biology
Joost Neijssen, Rosa M. F. Cardoso, Kristen M. Chevalier, Luus Wiegman, Thomas Valerius, G. Mark Anderson, Sheri L. Moores, Janine Schuurman, Paul W. H. Parren, William R. Strohl, Mark L. Chiu
Summary: This study focused on developing a bispecific antibody targeting EGFR and MET pathways to overcome resistance to targeted therapies in nonsmall cell lung cancer patients. By sequentially screening a panel of BsAbs and selecting the optimal bispecific molecule, amivantamab was generated and demonstrated superior antitumor activity in preclinical models. The unique mode of action of amivantamab may provide benefits to patients with malignancies associated with aberrant EGFR and MET signaling.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Oncology
Arpita S. Pal, Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates, Andrea L. Kasinski
Summary: EGFR inhibitors are commonly used to treat NSCLC with EGFR alterations, but resistance to these treatments remains a significant challenge. This study identifies the loss of the epigenetic factor KMT5C as a driver of EGFR inhibitor resistance by promoting the activation of a bypass mechanism involving the oncogenic long noncoding RNA LINC01510 and the oncogene MET. These findings provide insights into the mechanisms of resistance and suggest potential targets for improving NSCLC treatment.
Article
Oncology
Boning Cai, Xiaomo Li, Xiang Huang, Tonghui Ma, Baolin Qu, Wei Yu, Wei Yang, Pei Zhang, Jing Chen, Fang Liu
Summary: EGFR tyrosine kinase inhibitors are standard treatment for NSCLC patients, but resistance is common. Combination of EGFR and MET inhibitors has shown promise, but acquired resistance to MET inhibitors is a challenge. Sequential MET inhibitor use may be effective for EGFR-mutant, MET-amplified NSCLC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Felipe J. F. Coimbra, Wilson Luiz da Costa, Heber S. C. Ribeiro, Alessandro L. Diniz, Andre Luis de Godoy, Igor Correia de Farias, Antonio Moris Cury Filho, Marcello Ferretti Fanelli, Maria Dirlei F. S. Begnami, Fernando Augusto Soares
ANNALS OF SURGICAL ONCOLOGY
(2016)
Article
Oncology
Tadeu Ferreira Paiva, Victor Hugo Fonseca de Jesus, Raul Amorim Marques, Alexandre Andre Balieiro Anastacio da Costa, Mariana Petaccia de Macedo, Patricia Maria Peresi, Aline Damascena, Benedito Mauro Rossi, Maria Dirlei Begnami, Vladmir Claudio Cordeiro de Lima
Article
Pathology
Mariana Petaccia de Macedo, Fernanda Machado de Melo, Bianca Cristina Garcia Lisboa, Louise D. Brot Andrade, Maria Dirlei Ferreira de Souza Begnami, Samuel Aguiar Junior, Heber Salvador de Castro Ribeiro, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck da Cunha
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2015)
Letter
Dermatology
Tatiana Cristina Moraes Pinto Blumetti, Marcela Pecora Cohen, Elimar Elias Gomes, Mariana Petaccia de Macedo, Maria Dirlei Ferreira de Souza Begnami, Jose Humberto Tavares Guerreiro Fregnani, Joao Pedreira Duprat, Giovanni Pellacani, Gisele Gargantini Rezze
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2015)
Article
Gastroenterology & Hepatology
Chiang J. Tyng, Maria Fernanda A. Almeida, Paula N. V. Barbosa, Almir G. V. Bitencourt, Jose Augusto A. G. Berg, Macello S. Maciel, Felipe J. F. Coimbra, Luiz Henrique O. Schiavon, Maria Dirlei Begnami, Marcos D. Guimaraes, Charles E. Zurstrassen, Rubens Chojniak
WORLD JOURNAL OF GASTROENTEROLOGY
(2015)
Article
Oncology
Wilson L. Costa, Henrique Mantoan, Rafael Horacio Brito, Heber S. C. Ribeiro, Alessandro L. Diniz, Andre Luis Godoy, Igor Correia Farias, Maria Dirlei F. S. Begnami, Fernando Augusto Soares, Felipe J. F. Coimbra
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2015)
Article
Oncology
Natalia M. Borges, Marcela do Vale Elias, Veruska L. Fook-Alves, Tathiana A. Andrade, Marina Lourenco de Conti, Mariana Petaccia Macedo, Maria Dirlei Begnami, Antonio Hugo J. F. M. Campos, Leina Yukari Etto, Adriana Bruscato Bortoluzzo, Antonio C. Alves, Ken H. Young, Gisele W. B. Colleoni
Article
Oncology
Antuani R. Baptistella, Marcos Vinicios Salles Dias, Samuel Aguiar, Maria D. Begnami, Vilma R. Martins
Review
Oncology
Carlos Gil Ferreira, Maria Isabel Achatz, Patricia Ashton-Prolla, Maria Dirlei Begnami, Fabricio K. Marchini, Stephen Doral Stefani
Article
Oncology
Wilson Luiz da Costa, Felipe J. F. Coimbra, Heber S. C. Ribeiro, Alessandro L. Diniz, Andre Luis de Godoy, Igor Correia de Farias, Maria Dirlei F. S. Begnami, Fernando Augusto Soares
ANNALS OF SURGICAL ONCOLOGY
(2015)
Article
Pathology
Mariana Petaccia de Macedo, Luiz Guilherme Cernaglia Aureliano de Lima, Maria Dirlei Ferreira de Souza Begnami, Fernanda Machado de Melo, Louise D. Brot Andrade, Bianca Cristina Garcia Lisboa, Luisa Martelli Soares, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck da Cunha
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2014)
Article
Pathology
Carolina Vieira de Castro, Gustavo Guimaraes, Samuel Aguiar, Ademar Lopes, Glauco Baiocchi, Isabela Werneck da Cunha, Antonio Hugo Jose Froes Marques Campos, Fernando Augusto Soares, Maria Dirlei Begnami
Letter
Pathology
Mariana Petaccia de Macedo, Louise D. Brot Andrade, Victor Piana Andrade, Jose Vassallo, Antonio Hugo J. F. M. Campos, Clovis Antonio Lopes Pinto, Cynthia Aparecida Bueno Toledo de Osorio, Maria Dirlei Ferreira de Souza Begnami, Dirce Maria Carraro, Fernando Augusto Soares, Isabela Werneck da Cunha
JOURNAL OF CLINICAL PATHOLOGY
(2014)
Editorial Material
Dermatology
Juliana Casagrande Tavoloni Braga, Elimar Gomes, Mariana Petaccia Macedo, Clovis Pinto, Joao Duprat, Maria Dirlei Begnami, Gisele Gargantini Rezze
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2014)
Article
Multidisciplinary Sciences
Aderbal R. T. Silva, Ana Cecilia Feio Santos, Jose M. Farfel, Lea T. Grinberg, Renata E. L. Ferretti, Antonio Hugo Jose Froes Marques Campos, Isabela Werneck Cunha, Maria Dirlei Begnami, Rafael M. Rocha, Dirce M. Carraro, Carlos Alberto de Braganca Pereira, Wilson Jacob-Filho, Helena Brentani